kabutan

SanBio Company Limited(4592) Summary

4592
TSE Growth
SanBio Company Limited
1,647
JPY
-55
(-3.23%)
Dec 12, 3:30 pm JST
10.57
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
1,611
Dec 13, 1:58 am JST
Summary Chart Historical News Financial Result
PER
PBR
119
Yield
ー%
Margin Trading Ratio
159.54
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
1,689 JPY 10.86 USD
Previous Close Dec 11
1,702 JPY 10.90 USD
High Dec 12, 9:03 am
1,708 JPY 10.97 USD
Low Dec 12, 1:48 pm
1,591 JPY 10.21 USD
Volume
2,700,400
Trading Value
4.43B JPY 0.03B USD
VWAP
1638.85 JPY 10.52 USD
Minimum Trading Value
164,700 JPY 1,057 USD
Market Cap
0.13T JPY 0.83B USD
Number of Trades
6,791
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
7,995
1-Year High Oct 17, 2025
46,775
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 18,600 6,396,300 343.89
Nov 28, 2025 11,800 7,036,700 596.33
Nov 21, 2025 14,400 7,069,400 490.93
Nov 14, 2025 9,800 7,231,500 737.91
Nov 7, 2025 9,900 7,277,300 735.08
Company Profile
SanBio Company Limited is a biotech venture specializing in the development of regenerative cell therapies. Their products show promise for treating neurological disorders.
Sector
Pharmaceuticals
SanBio Company Limited is a biotech venture primarily focused on the research and development of regenerative cell medicines. Founded in the United States, the company later expanded into Japan. Their flagship product, SB623, is an allogeneic neural regenerative cell therapy targeting central nervous system disorders. The company has submitted a regulatory application in Japan for chronic traumatic brain injury and aims to expand its indications to include stroke and intracerebral hemorrhage. SanBio possesses proprietary cell culture and manufacturing technologies and has secured product supply rights. Given SB623's strong neuroprotective properties, the company is also exploring its potential in other conditions such as retinal diseases. SanBio employs a business model that combines in-house development with licensing agreements with partner companies. The company places a strong emphasis on securing intellectual property rights and is pursuing a business strategy with global expansion in mind.